Get Ready for Hep C Meds Maviret and Vosevi
You'll see big changes in treating hepatitis C due to the new oral antivirals, Maviret and Vosevi.
Maviret (MAV-ih-reht, glecaprevir/pibrentasvir) will be another game changer. It's the first hep C med approved for just 8 weeks for initial therapy of all genotypes for most patients without cirrhosis.
It'll also be the lowest priced option at about $43,000/course...compared to $68,000 for Harvoni or $61,000 for Epclusa for 12 weeks.